These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37526850)

  • 1. Update on Regulation of Regenerative Medicine in Taiwan.
    Chao WY; Chang YT; Tsai YT; Huang MC; Lin YC; Wu MM; Chi JF; Lin CL; Cheng HF; Wu SM
    Adv Exp Med Biol; 2023; 1430():211-219. PubMed ID: 37526850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Cell and Gene Therapy Medicinal Products in Taiwan.
    Lin YC; Wang PY; Tsai SC; Lin CL; Tai HY; Lo CF; Wu SI; Chiang YM; Liu LL
    Adv Exp Med Biol; 2015; 871():181-94. PubMed ID: 26374219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.
    Azuma K; Yamanaka S
    Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
    Sato Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current status of the regulation and development of cell therapy products in Japan].
    Igarashi Y; Sato Y
    Nihon Yakurigaku Zasshi; 2018; 151(6):254-259. PubMed ID: 29887575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory Frameworks for Gene and Cell Therapies in Japan.
    Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
    Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem Cell and Regenerative Medicine Global Conference (SCRGC) 2016 (August 23-24, 2016 - Gyeonggi-do, Korea).
    Vertès A
    Drugs Today (Barc); 2016 Oct; 52(10):577-583. PubMed ID: 27910966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation].
    Mahalatchimy A; De Grove-Valdeyron N
    J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory Aspects of Cell and Gene Therapy Products: The Japanese Perspective.
    Maruyama Y; Noda S; Okudaira S; Sakurai A; Okura N; Honda F
    Adv Exp Med Biol; 2023; 1430():155-179. PubMed ID: 37526847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Governmental Regulatory System for Stem Cell-Based Therapies in Japan.
    Hara A; Sato D; Sahara Y
    Ther Innov Regul Sci; 2014 Nov; 48(6):681-688. PubMed ID: 30227468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects of Advanced Therapy Medicinal Products-Based Therapies in Regenerative Dentistry: Current Status, Comparison with Global Trends in Medicine, and Future Perspectives.
    Bakopoulou A
    J Endod; 2020 Sep; 46(9S):S175-S188. PubMed ID: 32950189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.
    Nagai S; Ozawa K
    Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.
    Inokuma Y
    Drug Saf; 2017 Jun; 40(6):475-482. PubMed ID: 28299610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory perspectives of Japan.
    Kusakabe T
    Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoption of Regulations for Cell Therapy Development: Linkage Between Taiwan and Japan.
    Tsai TH; Ling TY; Lee CH
    Clin Transl Sci; 2020 Nov; 13(6):1045-1047. PubMed ID: 32407601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
    Viswanathan S; Bubela T
    Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
    Okada K; Koike K; Sawa Y
    Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regenerative medicine legislation in Japan for fast provision of cell therapy products.
    Fujita Y; Kawamoto A
    Clin Pharmacol Ther; 2016 Jan; 99(1):26-9. PubMed ID: 26482927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cell therapy clinical research: A regulatory conundrum for academia.
    Nagpal A; Juttner C; Hamilton-Bruce MA; Rolan P; Koblar SA
    Adv Drug Deliv Rev; 2017 Dec; 122():105-114. PubMed ID: 27760370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative regenerative medicines in the EU: a better future in evidence?
    Corbett MS; Webster A; Hawkins R; Woolacott N
    BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.